Beyond Plaques: Can We Repair the Brain's Own Natural Cleaning System?

For years, Alzheimer's research has focused on a straightforward question: How do we remove amyloid from the brain?

That question has led to important advances. Medications like lecanemab and donanemab bind to amyloid plaques and help the immune system remove them. They don't stop Alzheimer's disease, but they have been shown to modestly slow cognitive decline in carefully selected patients with early symptomatic disease.

A newly published study approached the problem from an entirely different angle.

Instead of asking how to remove amyloid, researchers asked whether one of the brain's own natural waste clearance systems could be repaired. If the brain already has mechanisms to clear amyloid under normal conditions, perhaps restoring those systems could help remove amyloid without directly targeting the plaques themselves.

The research is still in its earliest stages, and it has only been tested in mice. Even so, it reflects a broader shift happening throughout Alzheimer's research. Increasingly, scientists are looking beyond amyloid itself and asking why the brain loses its ability to keep itself healthy in the first place.

The Brain Is Constantly Cleaning Itself

Amyloid isn't inherently abnormal. Healthy brains produce amyloid-beta throughout life as part of normal cellular activity. Under ordinary circumstances, those proteins are continuously removed before they can accumulate into plaques.

The brain accomplishes this through several overlapping clearance systems. Some waste products are transported across the blood-brain barrier into the bloodstream, while others are removed through the glymphatic system, a network that appears to become particularly active during sleep.^1,2

As we age, those clearance mechanisms become less efficient. Alzheimer's disease appears to accelerate that process. Instead of maintaining a balance between amyloid production and removal, the brain gradually begins to fall behind.

One of the proteins involved in that process is P-glycoprotein (P-gp), a transporter located within the blood-brain barrier. P-glycoprotein functions somewhat like an export pump, helping move amyloid-beta out of the brain and into the circulation where it can ultimately be eliminated. Studies have shown that P-glycoprotein activity is reduced in Alzheimer's disease, potentially contributing to amyloid accumulation over time.³

Unfortunately, P-glycoprotein function can't currently be measured in routine clinical practice. For now, researchers are studying it as a potential therapeutic target rather than a diagnostic test.

Instead of developing another therapy that directly attacks plaques, researchers wondered whether restoring one of these natural clearance pathways might allow the brain to do more of the work itself.

A Different Therapeutic Strategy

The compound studied is known as Cu(ATSM).

Although media reports often describe it as a "copper compound," that description can be misleading. Cu(ATSM) is not simply copper. It is a laboratory-designed molecule that tightly binds copper within a specific chemical structure. That structure allows the compound to cross the blood-brain barrier and deliver copper in ways that ordinary dietary copper cannot.

Cu(ATSM) isn't an entirely new molecule. It has already entered human clinical development for other neurological conditions, including amyotrophic lateral sclerosis (ALS) and Parkinson disease. While it has not been approved for those conditions, those earlier studies have provided researchers with valuable information about its dosing, pharmacology, and tolerability in humans.⁴ If future Alzheimer's studies continue to show promise, having that foundation in place could help accelerate clinical development.

In this study, investigators treated APP/PS1 mice, a commonly used model of Alzheimer's disease, for 56 days.

Compared with untreated animals, mice receiving Cu(ATSM) demonstrated a 24.1% restoration of P-glycoprotein expression at the blood-brain barrier, an approximately 42% reduction in cortical amyloid-beta 42 levels, and significant improvement in long-term spatial memory testing.⁵

The findings suggest that restoring P-glycoprotein activity may enhance the brain's ability to remove amyloid by supporting one of its normal clearance pathways, rather than relying on direct immune-mediated removal.

Please Don't Head to the Vitamin Aisle Just Yet

One point is worth emphasizing before anyone reaches for a bottle of copper supplements.

It is incredibly important to understand that this compound is completely different from the copper supplements you can buy over the counter.

Cu(ATSM) behaves very differently from nutritional copper. The therapeutic effects observed in this study depend on the compound's unique chemical structure, which determines how it is transported throughout the body and into the brain. Simply taking copper supplements has never been shown to prevent, slow, or treat Alzheimer's disease.

In fact, taking too much copper can be harmful. Excessive copper intake may cause gastrointestinal symptoms, liver injury, and other toxic effects. At this time, there is no evidence that commercially available copper supplements reproduce the effects seen with Cu(ATSM), and this study should not be interpreted as support for self-treatment.

Could This Reduce the Risk of ARIA?

One of the most interesting questions raised by this study wasn't actually answered by the study itself.

Current anti-amyloid antibodies remove plaques by binding directly to amyloid and recruiting the immune system to clear it. While those medications have demonstrated clinical benefit, they also carry a known risk of amyloid-related imaging abnormalities (ARIA), which can cause swelling or small areas of bleeding in the brain. That risk is highest among people who carry two copies of the APOE ε4 gene and those with significant cerebral amyloid angiopathy.^6–8

Cu(ATSM) appears to work through a different biological pathway. Rather than targeting plaques directly, it may enhance one of the brain's normal waste export systems.

Whether that difference would translate into a lower risk of ARIA remains completely unknown. This study was performed in mice and was not designed to evaluate ARIA. Animal models also do not reliably reproduce the vascular changes seen in people with Alzheimer's disease.

Even so, the concept is intriguing. If future clinical trials demonstrate that enhancing physiologic amyloid clearance can safely reduce amyloid accumulation, this approach could someday become particularly relevant for patients who are at higher risk for complications from antibody therapy. That possibility remains speculative, but it represents an important area for future research.

A Shift in How We Think About Alzheimer's Disease

One of the themes emerging from recent Alzheimer's conferences is that researchers are increasingly trying to restore normal brain biology rather than simply remove a single abnormal protein.

Blood-brain barrier function, vascular health, inflammation, sleep, glymphatic clearance, synaptic resilience, mitochondrial function, and tau pathology are all being actively investigated as therapeutic targets. Amyloid remains an important part of the story, but it is no longer viewed in isolation.

This study fits neatly into that broader trend.

Instead of asking only how to eliminate plaques, researchers are beginning to ask why the brain stopped clearing them in the first place. Those are different questions, and they may ultimately require different treatments.

What This Means for Patients and Caregivers

As hopeful as this sounds, we always have to remember a hard truth in medicine: mice are not humans.

Cu(ATSM) is not an approved treatment for Alzheimer's disease. Countless therapies that produce exciting results in laboratory animals ultimately fail when they are tested in people. At this point, we simply don't know whether this approach will slow cognitive decline in humans.

Still, studies like this are encouraging because they reflect how Alzheimer's research continues to evolve. Every year, scientists learn more about why the disease develops and, just as importantly, why the brain gradually loses its ability to protect itself. Some discoveries become new medications. Others simply point researchers in a better direction.

This study doesn't mean we've found a cure, and it certainly doesn't mean people should expect Cu(ATSM) to become the next Alzheimer's drug. What it does show is that researchers are beginning to think differently. Instead of focusing solely on removing amyloid after it accumulates, they're also asking whether we can restore the systems that were supposed to clear it all along.

That shift in thinking may prove to be just as important as the next drug that reaches the market.

References

1. Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science. 2020;370(6512):50-56. doi:10.1126/science.abb8739
2. Hablitz LM, Nedergaard M. The glymphatic system. Curr Biol. 2021;31(20):R1371-R1375. doi:10.1016/j.cub.2021.08.026
3. Behl T, Kaur I, Sehgal A, et al. The interplay of ABC transporters in Aβ translocation and cholesterol metabolism: Implicating their roles in Alzheimer's disease. Mol Neurobiol. 2021;58(4):1564-1582. doi:10.1007/s12035-020-02211-x
4. Nikseresht S, Hilton JB, Kysenius K, et al. Copper-ATSM as a treatment for ALS: Support from mutant SOD1 models and beyond. Life (Basel). 2020;10(11):271. doi:10.3390/life10110271
5. Pyun J, Noor A, Runwal P, et al. Cu(ATSM) restores blood-brain barrier abundance of P-glycoprotein and improves cognitive function in the APP/PS1 mouse model of Alzheimer's disease. ACS Chem Neurosci. 2026;17(12):2389-2405. doi:10.1021/acschemneuro.6c00252
6. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948
7. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527. doi:10.1001/jama.2023.13239
8. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023;10(3):362-377. doi:10.14283/jpad.2023.30